Brett L. Carlson

Mayo Clinic, Rochester

Research Area

Biography

Brett L. Carlson has not added Biography.
If you are Brett L. Carlson and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title	2026

Other Publications

Article	Year
PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 18559622	2008
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro-oncology\| PubMed ID: 18952979	2009
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Molecular cancer therapeutics\| PubMed ID: 19174557	2009
Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. International journal of radiation oncology, biology, physics\| PubMed ID: 19695438	2009
Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance. Journal of neuro-oncology\| PubMed ID: 20443131	2010
Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 22675172	2012
p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro-oncology\| PubMed ID: 22711607	2012
Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 24838527	2014
The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 25609063	2015
Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses. PloS one\| PubMed ID: 25933216	2015
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. Molecular cancer therapeutics\| PubMed ID: 26438157	2015
Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance wi... The Journal of pharmacology and experimental therapeutics\| PubMed ID: 26604245	2016
Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. Journal of the National Cancer Institute\| PubMed ID: 26615020	2016
Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins. Cell reports\| PubMed ID: 26972001	2016
Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastom... The Journal of pharmacology and experimental therapeutics\| PubMed ID: 28847917	2017
Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma. Molecular cancer therapeutics\| PubMed ID: 28947502	2017
Quantifying the setup uncertainty of a stereotactic murine micro-image guided radiation therapy system. The British journal of radiology\| PubMed ID: 30299986	2019
Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. Neuro-oncology\| PubMed ID: 31121035	2019
Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 31852831	2020
Imaging and Dosimetry Study of Inter-fraction Setup Error in a Murine Xenograft Flank Tumor Radiation Model. Radiation research\| PubMed ID: 31877254	2020
Radiation Induced Metabolic Alterations Associate With Tumor Aggressiveness and Poor Outcome in Glioblastoma. Frontiers in oncology\| PubMed ID: 32432031	2020
Efficacy of Tesevatinib in -Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling. Molecular cancer therapeutics\| PubMed ID: 33785646	2021
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma. Neuro-oncology\| PubMed ID: 34050676	2021
Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules. Neuro-oncology\| PubMed ID: 34232318	2022
Preclinical Risk Evaluation of Normal Tissue Injury With Novel Radiosensitizers. International journal of radiation oncology, biology, physics\| PubMed ID: 34400266	2021
RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma. Neuro-oncology\| PubMed ID: 35231103	2022
Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts. Neuro-oncology advances\| PubMed ID: 36071925	2022
WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse models. Neuro-oncology advances\| PubMed ID: 37324218	2023
Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts. Molecular cancer therapeutics\| PubMed ID: 38224566	2024
Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization. Science translational medicine\| PubMed ID: 38354228	2024
Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 38743766	2024
ATM inhibition exploits checkpoint defects and ATM-dependent double strand break repair in TP53-mutant glioblastoma. Nature communications\| PubMed ID: 38906885	2024
Factors Influencing the Central Nervous System (CNS) Distribution of the Ataxia Telangiectasia Mutated and Rad3-Related Inhibitor Elimusertib (BAY1895344): Implications for the Treatment of ... The Journal of pharmacology and experimental therapeutics\| PubMed ID: 39284626	2024
DNA-PK Inhibition Shows Differential Radiosensitization in Orthotopic GBM PDX Models Based on DDR Pathway Deficits. Molecular cancer therapeutics\| PubMed ID: 39440433	2025
Modeling the Acute Mucosal Toxicity of Fractionated Radiotherapy Combined with the ATM Inhibitor WSD0628. Molecular cancer therapeutics\| PubMed ID: 39559836	2025
The impact of therapeutic radiation on drug distribution across the blood-brain barrier in normal mouse brain and orthotopic glioblastoma tumors. Neuro-oncology\| PubMed ID: 40163716	2025
The novel brain penetrant ataxia-telangiectasia mutated inhibitor WSD0628 provides robust radiosensitization of brain tumor patient-derived xenografts. Neuro-oncology\| PubMed ID: 40230030	2025
Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-Wild-type Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 40591434	2025
Transcriptomic analysis identifies a potential target for bevacizumab resistant glioblastoma. Scientific reports\| PubMed ID: 41125665	2025
Optimizing procedures for ocular radiation injury studies in the tree shrew. Exploration of targeted anti-tumor therapy\| PubMed ID: 41357135	2025
Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts. Neuro-oncology advances\| PubMed ID: 41664821	2026